Idorsia Ltd - Special Call Transcript
Dear ladies and gentlemen, welcome to the Idorsia conference call. At our customers' request, this conference will be recorded. (Operator Instructions) May I now hand you over to Andrew Weiss, who will lead you through this conference. Please go ahead, sir.
Thank you, Kai. Good morning, good afternoon, everyone. This is Andrew Weiss, Head of Investor Relations and Corporate Communications here at Idorsia. I welcome you to today's call to discuss the second set of Phase III results for daridorexant in insomnia. In the call with me today are our CEO, Jean-Paul Clozel; and our Global Head of Clinical Development, Guy Braunstein. Both are here to walk you through our presentation and prepared remarks, which will then be followed up with a Q&A session. In that session, Martine Clozel will be able to also take questions. Next slide, please.
I do need to remind everybody that we will be making forward-looking statements. Therefore, you have been properly warned about
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |